At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed May 11, 2026 at 07:00 ET
Alpha Tau reported groundbreaking interim data from its REGAIN trial for recurrent glioblastoma, showing complete responses in 2 of the first 3 patients with total disappearance of tumor lesions. The data is early (n=3) but highly promising in a devastating disease with few effective treatments, supporting the company's core strategy and potential FDA advancement.
- First 2 of 3 patients demonstrated complete response (total disappearance of all enhancing tumor lesions) per RANO criteria
- Third patient showed stable disease with 30% decrease in tumor dimension
- No local or distant recurrence in any patient as of May 3, 2026 cutoff
- One grade 3 SAE (seizure with temporary paralysis) observed, which resolved with steroids
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access